Based on significant benefit for lung cancer treatment and promising results from a phase II study in relapsed ovarian cancer (16, 17), another oral triple angiokinase inhibitor nintedanib (BIBF 1120) targeting VEGFR, PDGFR, and FGFR was studied for first-line therapy of ovarian cancer patients. This evidence concerns the gene KDR and ovarian cancer.